Chapter title |
Treatment of Pancreatic Cancer by Aptamer Conjugated C/EBPα-saRNA
|
---|---|
Chapter number | 12 |
Book title |
RNA Activation
|
Published in |
Advances in experimental medicine and biology, June 2017
|
DOI | 10.1007/978-981-10-4310-9_12 |
Pubmed ID | |
Book ISBNs |
978-9-81-104309-3, 978-9-81-104310-9
|
Authors |
Sorah Yoon, John J. Rossi |
Editors |
Long-Cheng Li |
Abstract |
Pancreatic cancer is estimated to become the second-leading cause of cancer-related mortality by 2020. While the death rates of most other cancers continue to decline recently, the death rates of pancreatic cancer are still increasing, with less than 5% of patients achieving 5-year survival. Despite great efforts to improve treatment with combinational therapies in pancreatic cancer patients, limited progress has been made. V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) has been depicted as a therapeutic target in pancreatic cancer for many years. However, the clinical outcome of KRAS-directed therapies has not been successful, suggesting that KRAS is an undruggable target. For the new druggable target, epigenetically silenced transcriptional factor C/EBPα (CCAAT/enhancer-binding protein α), upregulator of a strong inhibitor of cell proliferation (p21), is upregulated by small activating RNA (saRNA) in pancreatic cancer. For the cell type-specific delivery, pancreatic cancer-specific 2'-Fluoropyrimidine RNA-aptamers (2'F-RNAs) are conjugated with C/EBPα-saRNA via sticky bridge sequences. The conjugates of aptamer-C/EBPα-saRNA upregulate the expression of C/EBPα in vitro and inhibit the tumor growth in vivo. It suggests that aptamer-mediated targeted delivery of therapeutic C/EBPα-saRNA might be the effective therapeutics under the current therapeutic modality failure in pancreatic cancer. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 12 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 4 | 33% |
Researcher | 2 | 17% |
Other | 2 | 17% |
Unknown | 4 | 33% |
Readers by discipline | Count | As % |
---|---|---|
Pharmacology, Toxicology and Pharmaceutical Science | 2 | 17% |
Medicine and Dentistry | 2 | 17% |
Chemistry | 2 | 17% |
Biochemistry, Genetics and Molecular Biology | 1 | 8% |
Engineering | 1 | 8% |
Other | 0 | 0% |
Unknown | 4 | 33% |